Company / Operating Cash Flow
Celldex Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$210.9M
FY2025
5-year range
-$210.9M / -$60.9M
FY2021-FY2025
Trend
-33.7%
vs FY2024
Sector context
#159 of 163
Health Care
What the data says
Among 163 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 2% for operating cash flow. Operating Cash Flow has declined for 5 consecutive years, from -$40M in FY2020 to -$211M in FY2025.
Based on SEC 10-K filings.
-$211M in FY2025.
Declined from -$107M to -$211M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 163This company -$210.9M Sector average $1.0B
▼
-120.2% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 33.7% year-over-year.
- Ranks #159 out of 163 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$210.9M | -33.7% |
| FY2024 | -$157.8M | -47.1% |
| FY2023 | -$107.3M | -3.4% |
| FY2022 | -$103.7M | -70.3% |
| FY2021 | -$60.9M | -50.7% |
| FY2020 | -$40.4M | +13.0% |
| FY2019 | -$46.4M | +58.9% |
| FY2018 | -$113.0M | -13.1% |
| FY2017 | -$99.9M | +11.6% |
| FY2016 | -$113.0M | -14.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026